Loading stock data…
XNCR
$12.38-0.06 (-0.48%)
Pre-Market$12.33-0.05 (-0.40%)· Last close May 13
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Xencor, Inc. in the Healthcare sector is trading at $12.38. Wall Street consensus targets $28.50 (12 analysts), implying a +130.2% move over the next 12 months. The stock is currently 34% below its 52-week high of $18.69, remaining 0.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +130.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$12.38
Potential Downside
0%
Whystock Fair Value$12.38
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$28.50+130.2%
Range$14.00 – $43.00
Fundamentals
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$942.40M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.92%
Volume
Today's trading volume
732,394
Recent News
These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat
Market forces rained on the parade of Xencor, Inc. ( NASDAQ:XNCR ) shareholders today, when the analysts downgraded...
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of -164.58% and -75.38%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026
Xencor (NASDAQ:XNCR) used a webcast during Digestive Disease Week 2026 to highlight Phase I results for its TL1A-targeting monoclonal antibody XmAb942 and to outline preclinical data supporting XmAb412, a bispecific antibody designed to inhibit both TL1A and IL-23p19. Charles Liles, Xencor’s head o
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
Corcept (CORT) delivered earnings and revenue surprises of -1.11% and -4.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls
Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls